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ABSTRACT
Objectives: Patient-reported outcome measures
(PROMs) collected in clinical trials should be
administered in a standardised way across sites and
routinely screened for avoidable missing data in order
to maximise data quality/minimise risk of bias. Recent
qualitative findings, however, have raised concerns
about the consistency of PROM administration in UK
trials. The purpose of this study was to determine the
generalisability of these findings across the wider
community of trial personnel.
Design: Online cross-sectional survey.
Setting: Participants were recruited from 55 UK
Clinical Research Collaboration Registered Clinical
Trials Units and 19 Comprehensive Local Research
Networks.
Participants: Research nurses, data managers/
coordinators, trial managers and chief/principal
investigators involved in clinical trials collecting
PROMs.
Analysis: We undertook descriptive analyses of the
quantitative data and directed thematic analysis of free-
text comments. Factors associated with the
management of missing PRO data were explored using
logistic regression.
Results: Survey data from 767 respondents supported
the generalisability of qualitative study findings,
suggesting inconsistencies in PROM administration
with regard to: the level of assistance given to trial
participants; the timing of PROM completion in relation
to the clinical consultation; and the management of
missing data. Having ≥10 years experience in a
research role was significantly associated with the
appropriate management of missing PROM data
(OR 2.26 (95% CI 1.06 to 4.82), p=0.035). There was
a consensus that more PROM guidance was needed in
future trials and agreement between professional
groups about the necessary components.
Conclusions: There are inconsistencies in the way
PROMs are administered by trial staff. Such
inconsistencies may reduce the quality of data and
have the potential to introduce bias. There is a need for
improved guidance in future trials that support trial
personnel in conducting optimal PROM data collection
to inform patient care.
INTRODUCTION
Patient-reported outcomes (PROs) are com-
monly measured in clinical trials in order to
evaluate the effectiveness of medical inter-
ventions from the point of view of patients.1
PRO trial data are collected using validated
questionnaires, known as patient-reported
outcome measures (PROMs). PROs trial
results can inform the healthcare decisions
made by patients and their clinicians,
support licensing claims for new medicines
and inﬂuence the development of health
policy, including decisions about cost-
effectiveness.2–4 In view of their importance,
there is a need to ensure rigorous PRO data
collection.
Unfortunately, missing PRO data can be a
problem in clinical trials. In a 2008 review of
285 randomised controlled trials (RCTs) col-
lecting PROs, Fielding et al5 found that 18%
Strengths and limitations of this study
▪ This study is the first to survey the opinions of
researchers and trial personnel regarding the
administration of patient-reported outcome mea-
sures in UK clinical trials.
▪ The large research nurse sample size should
allow generalisation of the results in this popula-
tion. Owing to their much smaller sample sizes,
caution should be exercised when generalising
the results from the remaining subgroups.
▪ Respondents were self-selecting and may
include those with more knowledge regarding
patient-reported outcomes (PROs); this should
be taken into account when interpreting the
results of the study.
▪ As the survey was anonymised, it was not pos-
sible to link staff together on a particular study.
Thus, further work is needed to definitively
establish whether the PRO administration vari-
ability seen in this survey may be present in a
single trial.
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reported between 11% and 20% missing data and a
further 18% reported >20% missing data. Such data are
generally considered ‘not missing at random’, rather
they may be missing from those participants with the
poorest outcomes, rendering it non-ignorable.6
Retrospective PRO data capture is frequently not pos-
sible; therefore, missing data of this type can result in
bias if such participants are concentrated in a particular
trial arm.6 7
Trials should therefore be designed to ensure that
PROMs are administered in a standardised way across
trial sites and are routinely screened for avoidable
missing data in order to maximise data quality and
reduce the risk of systematic bias.6 8–10 PROM administra-
tion guidance should, therefore, be included in the trial
protocol and in site start-up training, and may also be
incorporated into supporting trial documentation such
as standard operating procedures (SOPs).7 11 12 Recent
qualitative evidence, however, has raised concerns about
the conduct of PRO measurement in UK trials.13 The
study, conducted by the authors, outlined three main
ﬁndings.13 First, there were reported inconsistencies in
the way in which PROMs were administered that could
adversely affect the quality of PRO trial data and poten-
tially bias results. Second, there was a reported lack of
PRO-speciﬁc protocol content, training and education
available to trial staff. Third, data collection staff reported
being intermittently exposed to PROM data that caused
them to become concerned for the well-being of a trial
participant (also known as a ‘PRO alert’,14 box 1) and, in
the absence of trial level guidance, reported providing
off-protocol cointerventions. Some of these interventions
appeared to risk biasing the results of the trial.
The aim of this study was to determine the extent to
which our qualitative ﬁndings were generalisable to the
wider community of trial staff using a large-scale cross-
sectional national survey of UK-based trial personnel.
Survey respondents’ experiences of PRO alerts and their
management are presented in a separate publication.15
In this paper, we present the results of the survey speciﬁc
to PROM administration, with the following objectives:
1. To investigate reported inconsistencies in PROM
administration in trials.
2. To investigate a reported lack of PRO-speciﬁc trial
protocol content and training.
3. To determine what PRO-speciﬁc trial protocol
content and training respondents would like to see in
future trials.
METHODS
Survey design
An online survey (see online supplementary ﬁle 1) was
developed by investigators with PRO and ethics expert-
ise, and the content informed by the results of our quali-
tative study.13 The survey contained questions on: (1)
demographics, (2) the participants’ experiences of
PROM administration with reference to the most recent
trial in which they had been involved, (3) the provision
of PRO-speciﬁc guidance within the trial and (4) PRO
guidance/training they would like to see in future trials.
Most questions contained space for free-text comments,
to allow respondents to expand on their answers. The
survey was pilot-tested in a purposive sample of n=9
research nurses to ensure the content was clearly under-
stood and to establish the feasibility of the distribution/
collection methods. Additional free-text comment boxes
were added to the survey instruments following pilot
feedback. No other changes to the survey questions were
necessary.
Survey sample
The study recruitment methods have been reported else-
where.15 In brief, an anonymised online exploratory
cross-sectional national survey of UK research nurses,
data managers/coordinators, trial managers and chief
and principal investigators (CPIs) involved in clinical
trials using either a primary or secondary PRO was con-
ducted in 2013/2014. The survey was anonymised to
encourage respondents to freely discuss potentially con-
troversial aspects surrounding PRO assessment/PRO
alerts and to maximise responses. An email containing
information about the study, and a link to the online
survey, was distributed via 55 UK Clinical Research
Collaboration Registered Clinical Trials Units
(CRC-RCTUs) and 19 Comprehensive Local Research
Networks (CLRNs). Eligible individuals were invited to
click on the link and complete the survey.
Analysis
Descriptive quantitative analysis was undertaken for each
respondent group. Frequency distributions were used to
describe respondent characteristics and survey
responses. All analysis was conducted using SPSS (V.21,
IBM). An exploratory prespeciﬁed logistic regression
analysis was also undertaken to investigate which factors
were associated with the appropriate management of
missing PRO data by data collection staff, as this can rep-
resent an important potential source of bias. Existing lit-
erature recommends routine checking of completed
PROMs and subsequent ‘chasing’ of missing data.16
Thus, the dependent variable in the model was the
appropriate management of missing data, deﬁned as:
Box 1 Definitions
Patient-reported outcome (PRO)—‘… any report of the status of
a patient’s health condition that comes directly from the patient,
without interpretation of the patient’s response by a clinician or
anyone else’4
Patient-reported outcome measure (PROM)—A validated paper-
based or electronic psychometric questionnaire used to collect
PRO data
PRO alert—The exposure of data collection staff to PRO data dis-
playing ‘concerning levels of psychological distress or physical
symptoms that may require an immediate response’14
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‘whether the completed PROM was checked for missing
data and participants were subsequently asked to com-
plete missing items/questionnaires’. The independent
variables were: the role of the data collector (ie,
‘research nurse’ or ‘data manager/coordinator’); their
length of experience in the research role; whether
PRO-speciﬁc information was reportedly present in the
trial protocol; and whether PRO-speciﬁc information
was reportedly included in trial training. A minimum of
60 responses were required to satisfy the sample size
requirement for this regression analysis (15 per covari-
ate).17 Signiﬁcance was set at p<0.05.
DK undertook directed content analysis of the free-
text comments responses, using the data from the quali-
tative study13 to develop the initial research questions
and coding framework.18 Additional codes were devel-
oped as the analysis was conducted and the framework
was modiﬁed accordingly.18 JI formally reviewed all
coding to enhance trustworthiness, and any disagree-
ments about coding were discussed and resolved.
RESULTS
A total of 767 individuals responded to the online survey
(table 1). The respondents’ most recent experience of a
trial collecting PROMs was predominantly in the second-
ary care setting, with trials ranging across clinical special-
ities (most commonly oncology). Trials appeared to use
a number of different PROMs, of which the most
common were the ﬁve-dimension European Quality of
Life instrument (EQ-5D), Hospital Anxiety and
Depression scale (HADS), the Short-Form Health Survey
12-item (SF-12) and 36-item (SF-36) questionnaires, the
European Organisation for Research and Treatment of
Cancer Core Quality of Life Questionnaire (EORTC
QLQ-C30) and the Health Assessment Questionnaire
(HAQ). The survey results are presented in table 2 and
summarised below. Qualitative themes and illustrative
respondent quotations are also presented. A response
rate calculation is not appropriate for the study as ours
was a non-probability sample.19 Moreover, neither the
UK CRC-CTUs nor the NIHR CLRNs held data regard-
ing the number of staff involved in trials with a primary
or secondary PRO, so there was no way to determine a
denominator. However, in discussion with the CRC-CTU
coordinating centre and with CLRN contacts, we esti-
mate the total number of researchers receiving our
survey invite, including those individuals ineligible for
the study, was ∼1800; our sample represented 43% of
this number.
Inconsistencies in PROM administration
Participant assistance
Respondents were asked what level of assistance they
had given to participants completing PROMs during
their most recent relevant trial. 66.2% of research nurse
respondents reported giving no assistance. The remain-
der gave assistance in a variety of different ways. Of
these, 37.9% reported helping participants to under-
stand the questions, 36.9% reported reading the PROM
questions out to the participants and 23.0% reported
being given the answers by participants then ﬁlling in
the questionnaire on their behalf.
Timing of PROM completion
There were varying responses with regard to the timing
of questionnaire completion. 47.9% of nurses reported
that the timing with which they administered the PROM
varied (ie, it was ‘sometimes before’ and ‘sometimes
after’ the clinical consultation) during their most recent
trial. 9.3% reported routinely administering the PROM
after the consultation. Only 18.2% reported routinely
administering PROMs prior to the participant’s clinical
consultation, inline with suggested guidelines.20 21
Management of missing PRO data
77.3% of research nurses and 72.0% of data managers
reported routinely checking completed PROM question-
naires for missing data in their most recent trial.
However, of the total sample, only 49.9% research
nurses and 15.4% of data managers checked for missing
data and subsequently attempted to follow-up partici-
pants to complete the missing items. 27.6% of research
nurses and 76.0% of data mangers reported checking
PROM question responses for scoring errors (eg, where
two options were selected instead of one), which are
often logged as missing data. Of the total sample, just
21.2% research nurses and 9.8% of data managers
reported checking for scoring errors and subsequently
attempting to follow-up participants in order to correct
the errors.
Determinants of differences in the management of missing
data
The ﬁndings of the exploratory logistic regression ana-
lysis are available in online supplementary ﬁle 3. In the
ﬁnal model, only ‘10 years or more experience in the
research role’ was signiﬁcant (p=0.035). The odds of
individuals with such experience routinely checking and
chasing missing PROM data were 2.26 (95% CI 1.06 to
4.82) times higher than those with less experience.
There were no signiﬁcant associations between the
dependent variable and ‘the role of the data collector’
(p=0.45); ‘whether PRO-speciﬁc information was report-
edly provided in the trial protocol’ (p=0.94); or
‘whether PRO-speciﬁc information was reportedly
included in trial training’ (p=0.64).
Current PRO-specific protocol content and training
Survey respondents were questioned about the
PRO-speciﬁc protocol content and training delivered in
their most recent trial. Results are presented ﬁrst from
members of the trial management team (CPIs and trial
managers), and then from frontline data collection staff
(research nurses and data managers/coordinators).
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Protocol content and training provision
82.9% of CPIs and 70.9% of trial managers reported
giving instructions to trial staff on how to administer the
PROM questionnaire in their most recent relevant trial.
Respondents were asked what particular information was
provided to data collection staff. 93.1% of CPIs and
86.6% of trial managers reported providing information
about the purpose and/or importance of PROM data to
the trial and 75.9% and 52.4%, respectively, reported
giving information surrounding the relevance and rea-
soning behind individual PROM questions. One
hundred per cent of respondents in both groups
reported providing information on when to administer
the PROM questionnaire. Over three-quarters of CPIs
reported providing information on when to administer
the PROM during a clinic (78.6%); how much assistance
to give the participant during questionnaire completion
(86.2%); and how to check for, and deal with, missing
Table 1 Characteristics of respondents
Respondent characteristics (total=767)
No. (%)
research nurse
respondents*
(n=560)
No. (%) data
manager
respondents*
(n=41)
No. (%) trial
manager
respondents*
(n=129)
No. (%) chief
and principal
investigator
respondents*
(n=37)
Age, years
≤25 4 (0.7) 3 (7.9) 4 (3.1) 0 (0)
26–35 95 (17) 14 (36.8) 51 (39.5) 5 (13.5)
36–45 193 (34.5) 10 (26.3) 43 (33.3) 11 (29.7)
46–55 217 (38.8) 8 (21.1) 23 (17.8) 14 (37.8)
≥56 51 (9.1) 3 (7.9) 8 (6.2) 7 (18.9)
Years in research role
<1 51 (9.2) 4 (10.5) 12 (9.3) 0 (0)
1–3 208 (37.3) 13 (34.2) 42 (32.6) 11 (29.7)
4–6 147 (26.4) 7 (18.4) 31 (24) 4 (10.8)
7–9 50 (9) 4 (10.5) 12 (9.3) 5 (13.5)
≥10 101 (18.1) 10 (26.3) 32 (24.8) 17 (45.9)
Setting of most recent clinical trial collecting PROs†
Primary care 112 (20.7) 15 (39.5) 47 (37.9) 16 (44.4)
Secondary care 428 (79.3) 23 (60.5) 77 (62.1) 20 (56.6)
Clinical areas covered by most recent clinical trial collecting PROs†
Cardiovascular 69 (16.5) 3 (9.4) 10 (10) 0 (0)
Elderly care 17 (4.1) 2 (6.3) 10 (10) 2 (7.4)
General medicine 39 (9.3) 2 (6.3) 7 (7) 0 (0)
General practice 19 (4.5) 3 (9.4) 23 (23) 9 (33.3)
Neurology 51 (12.2) 1 (3.1) 9 (9) 4 (14.8)
Obstetrics and gynaecology 22 (5.3) 3 (9.4) 7 (7) 2 (7.4)
Oncology 119 (28.5) 15 (46.9) 28 (28) 1 (3.7)
Opthalmology 8 (1.9) 1 (3.1) 4 (4) 7 (25.9)
Orthopaedics 35 (8.4) 1 (3.1) 7 (7) 1 (3.7)
Paediatrics 35 (8.4) 2 (6.3) 9 (9) 6 (22.2)
Respiratory 41 (9.8) 5 (15.6) 8 (8) 3 (11.1)
Rheumatology 47 (11.2) 1 (3.1) 6 (6) 5 (18.5)
PROs used in trial†
EuroQol EQ-5D 401 (76.1) 25 (67.6) 99 (82.5) 24 (80)
Health Assessment Questionnaire (HAQ) 154 (29.2) 1 (2.7) 4 (3.3) 2 (6.7)
Nottingham Health Profile (NHP) 0 (0) 0 (0) 0 (0) 0 (0)
SF-12 Health Survey or SF-12v2 Health Survey 36 (6.8) 6 (16.2) 22 (18.3) 7 (23.3)
SF-36 Health Survey or SF-36v2 Health Survey 104 (19.7) 5 (13.5) 17 (14.2) 6 (20)
Hospital Anxiety and Depression scale (HAD) 115 (21.8) 4 (10.8) 21 (17.5) 11 (36.7)
Arthritis Impact Measurement Scales (AIMS2) 3 (0.6) 0 (0) 0 (0) 2 (6.7)
EORTC QLQ—C30 (Core Questionnaire) 106 (20.1) 9 (24.3) 18 (15) 0 (0)
Minnesota Living with Heart Failure
Questionnaire (MLHF)
9 (1.7) 0 (0) 1 (0.8) 1 (3.3)
Oxford Hip Score (OHS) 9 (1.7) 0 (0) 0 (0) 1 (3.3)
Oxford Knee Score (OKS) 14 (2.7) 1 (2.7) 0 (0) 0 (0)
Roland-Morris Disability Questionnaire (RMDQ) 2 (0.4) 0 (0) 2 (1.7) 4 (13.3)
*Columns may not add up to n due to missing values.
†Respondents could select multiple categories.
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PRO data (82.8%). The proportion of trial managers
who reported providing this information was uniformly
lower: 67.9%, 63.4% and 58.5%, respectively. 41.4% of
CPIs and 28.0% of trial managers reported providing
information on what action should be taken if partici-
pants had written additional information on their
PROM, or had attached further information (such as
letter to the trial team) to their PROM.
Protocol content and training available to frontline staff
92.2% of research nurses and 50.0% of data managers/
coordinators reported that the trial protocol had
included some form of PRO-speciﬁc information, with
87.7% and 76.9%, respectively, reporting that the
content was adequate for their needs. 32.7% of research
nurses and 39.1% of data managers/coordinators
reported receiving trial training that incorporated PRO
guidance. 94.4% of research nurses and 88.9% of data
managers/coordinators who reported receiving PRO
training felt it was adequate for their needs. 60.5% of
research nurses reported they had received an explan-
ation of why the PROM was being collected in the trial
and 87.7% felt conﬁdent they could explain this to parti-
cipants. 30.3% of research nurses reported receiving an
explanation regarding the relevance and reasoning
behind individual PROM questions and 59.9% felt conﬁ-
dent they could explain this to their participants.
Free-text comments relating to trial protocol content and
training
There were 40 free-text comments in this section, with
most appearing to suggest that, while nurses felt
PRO-speciﬁc information was generally present within
trial protocols, it could be limited in depth:
Usually there is reference to the fact that the question-
naires are to be completed. No other information is pro-
vided or instructions on use, administration etc.
(Research nurse)
A number of comments suggested that nursing staff
had received little in the way of PRO training:
I was not given any training on PROM basically just been
told if patients consent for the study they ﬁll this docu-
ment. (Research nurse)
Some research nurses suggested PROM training was
particularly lacking for staff joining the trial at a later
stage:
Our centre was invited to take part in the study quite late
on so missed the initial set up that other centres had.
Whilst there was some verbal communication regarding
how to deliver the questionnaires much of it was down to
previous experience/personal communication skills….
(Research nurse)
I took over the study partway through and received
minimal instruction relating to the questionnaires.
Anything additional I learn en route. (Research nurse)
Some reported that PRO trial training was inconsist-
ently delivered across trials:
I have been taught how to use it many times but not for
this study. However, to ensure consistency I believe we
should be trained on this for each study. (Research
nurse)
A number of comments implied that the impact of a
lack of guidance may be minimal. These nurses reported
either relying on either previous experience of PRO
assessment in trials, or knowledge gained via attendance
at previous training courses, or an independent search
for the information they required:
I have used QOL questionnaires a fair amount so felt
conﬁdent using the provided tools without needing train-
ing. (Research nurse)
No speciﬁc training given by the study centre for this
study, but I have completed training on many of the QoL
[PROMs] previously. (Research nurse)
The trial training said that the questionnaires had to be
done by the patient, but did not give any reasons why. I
did my own reading to ﬁnd out why this was the case.
(Research nurse)
Conversely, one respondent comment suggested a lack
of PROM guidance resulted in an impaired ability to
explain aspects surrounding PROM assessment to trial
participants:
I can roughly explain to participants why this information
is required, but would prefer to have a better understand-
ing myself to be able to fully explain this to study partici-
pants. (Research nurse)
and one respondent comment suggested it led to
more queries to the trial team:
The trial coordinator had to be contacted quite often for
clariﬁcation as subject asked questions that was not
covered in the training session. (Research nurse)
Future PRO-specific protocol content and training
Survey respondents were asked whether they felt more
PRO guidance was needed in future trials. While 85.1%
of research nurses and 78.6% of data managers/coordi-
nators ‘strongly agreed’ or ‘agreed’, there should be
more PRO guidance provided in future trials with PRO
end points, in contrast, only 58.2% of trial managers
and 56.5% of CPIs felt the same.
After considering a list of possibilities suggested by the
ﬁndings of our qualitative study, respondents were also
asked which particular PRO-speciﬁc items of information
they felt were needed and where should they be
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Table 2 Questionnaire responses
Survey questions and response options
No. (%) research
nurse
respondents* (n=560)
No. (%) data manager
respondents* (n=41)
No. (%) trial manager
respondents* (n=129)
No. (%) chief and principal
investigator respondents*
(n=37)
What assistance did you give to the trial participants during the completion of the questionnaire? (Last Trial)
I read the questions out to the participants 194 (36.9)† – – –
I helped participants to understand the questions 209 (39.7)† – – –
The participants gave me the answers and I filled in the
questionnaire
121 (23.0)† – – –
I gave no assistance, the participants filled in their
questionnaires independently
348 (66.2)† – – –
If the participant had to complete the quality of life or other patient-reported outcome measure questionnaire in clinic, when did they do so? (Last Trial)
Always before their consultant/doctor appointment 92 (18.2) – – –
Always after their consultant/doctor appointment 47 (9.3) – – –
Variable, sometimes before and sometimes after their
consultant/doctor appointment
242 (47.9) – – –
Not applicable 124 (24.6) – – –
Which of the following did you do after trial participants had completed their PROM? (Last Trial)
I sent the questionnaire to the data inputting centre without
looking at it
100 (19.6)† – – –
I looked at the completed questionnaire to see if the
participant had missed out any questions
394 (77.3)† – – –
If I discovered missing items, I prompted participants to
complete them
308 (60.4)† – – –
I looked at the completed questionnaire to see if there were
any scoring errors (eg, 2 options selected instead of 1,
scoring the wrong way round, etc)
141 (27.6)† – – –
If I suspected a scoring error, I prompted participants to
look again at some questions, to ensure they had
understood them correctly
137 (26.9)† – – –
Checked for missing PROM data and followed up
participant to rectify
277 (49.9)
Checked for PROM scoring errors and followed up
participant to rectify
114 (21.2)
When the quality of life/patient-reported outcome questionnaire data were inputted, which of the following occurred? (Last Trial)
The questionnaire was checked to see if the participant had
completed all questions
– 18 (72.0)† – –
If items were found to be missing, trial participants were
followed up in some way (eg, by post, by phone or via their
research nurse) in order to complete the questionnaire
– 7 (28.0)† – –
– 19 (76.0)† – –
Continued
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Table 2 Continued
Survey questions and response options
No. (%) research
nurse
respondents* (n=560)
No. (%) data manager
respondents* (n=41)
No. (%) trial manager
respondents* (n=129)
No. (%) chief and principal
investigator respondents*
(n=37)
The questionnaire was checked for scoring errors (eg, two
answers given instead of one, or reversed scoring)
If scoring errors were detected, trial participants were
followed up in some way (eg, by post, by phone or via their
research nurse) in order to correct them
– 4 (16.0)† – –
Checked for missing PROM data and followed up
participant to rectify
– 6 (15.4)
Checked for PROM scoring errors and followed up
participant to rectify
– 4 (9.8)
Were the staff involved in data collection given instructions on how to administer the quality of life/patient-reported outcome questionnaire? (Last Trial)
Yes – – 90 (70.9) 29 (82.9)
No – – 37 (29.1) 6 (17.1)
What particular information on quality of life/patient-reported outcome measurement was given to the data collection staff in the last trial you were involved with?
The purpose and/or importance of quality of life/
patient-reported outcome data to the trial
– – 71 (86.6) 27 (93.1)
Relevance and reasoning behind individual quality of life/
patient-reported outcome questions
– – 43 (52.4) 22 (75.9)
When to administer the questionnaire (time points) – – 84 (100) 29 (100)
When to administer the questionnaire during the clinic
appointment (before/during/after the consultation)
– – 53 (67.9) 22 (78.6)
How much assistance to give the participant during
questionnaire completion
– – 52 (63.4) 25 (86.2)
How to check for, and deal with, missing quality of life/
patient-reported outcome data
– – 48 (58.5) 24 (82.8)
What to do if participants write additional information on
their questionnaires (or attach a letter)
– – 23 (28.0) 12 (41.4)
Trial protocol and training questions
The trial protocol included information about quality of life/
patient-reported outcome measurement
474 (92.2) – – –
Reported PRO protocol content present and felt it was
adequate for their needs
415 (87.7) – – –
I received trial training that included information on quality
of life/patient-reported outcome measurement
164 (32.7) – – –
Reported receiving PRO training and felt it was adequate
for their needs
152 (94.4%) – – –
The trial protocol included information about quality of life/
patient-reported outcome data inputting
– 13 (50.0) – –
Reported PRO protocol content present and felt it was
adequate for their needs
– 10 (76.9) – –
– 9 (39.1) – –
Continued
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Table 2 Continued
Survey questions and response options
No. (%) research
nurse
respondents* (n=560)
No. (%) data manager
respondents* (n=41)
No. (%) trial manager
respondents* (n=129)
No. (%) chief and principal
investigator respondents*
(n=37)
I received trial training which included information on quality
of life/patient-reported outcome data inputting
Reported receiving PRO training and felt it was adequate
for their needs
– 8 (88.9) – –
PRO assessment explanation questions
It was explained to me why the quality of life/
patient-reported outcome measure data were being
collected in the trial
314 (60.5) – – –
I was confident I could explain to trial participants why the
quality of life/patient-reported outcome measure data were
being collected in the trial
456 (87.7) – – –
It was explained to me why each of the questions in the
quality of life/patient-reported outcome measure were
included, ie, how each was of relevance to the trial
157 (30.3) – – –
I was confident I could explain to trial participants why each
of the questions in the quality of life/patient-reported
outcome measure had been included, ie, how each was of
relevance to the trial
312 (59.9) – – –
Please read the following statements. In each case, please indicate whether you ‘strongly agree’, ‘agree’, have ‘no opinion’, ‘disagree’ or ‘strongly disagree’ with the
statement (Future Trials)
There should be more protocol content and trial training
covering quality of life/patient-reported outcome
measurement, in trials employing such outcomes
SA 140 (27.9)
A 283 (56.5)
NO 57 (11.4)
D 20 (4.0)
SD 1 (0.2)
– – –
There should be more quality of life/patient-reported
outcome measurement guidance contained within other
trial documentation, such as site manuals or standard
operating procedures, in trials employing such outcomes
SA 127 (25.4)
A 302 (60.4)
NO 52 (10.4)
D 18 (3.6) SD 1 (0.2)
– – –
Please read the following statements. In each case, please indicate whether you ‘strongly agree’, ‘agree’, have ‘no opinion’, ‘disagree’ or ‘strongly disagree’ with the
statement (Future Trials)
There should be more protocol content and trial training for
data managers/inputters, covering quality of life/
patient-reported outcome measurement
– SA 3 (10.7)
A 17 (60.7)
NO 2 (7.1)
D 6 (21.4)
SD 0 (0)
– –
There should be site manuals or standard operating
procedures available to data mangers/inputters that include
information on quality of life/patient-reported outcome
administration in the trial
– SA 6 (21.4)
A 18 (64.3)
NO 3 (10.7)
– –
Continued
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Table 2 Continued
Survey questions and response options
No. (%) research
nurse
respondents* (n=560)
No. (%) data manager
respondents* (n=41)
No. (%) trial manager
respondents* (n=129)
No. (%) chief and principal
investigator respondents*
(n=37)
D 1 (3.6)
SD 0 (0)
Please read the following statements. In each case, please indicate whether you ‘strongly agree’ (SA), ‘agree’ (A), have ‘no opinion’ (NO), ‘disagree’ (D) or ‘strongly
disagree’ (SD) with the statement (Future Trials)
Data collection staff in trials need more information on
quality of life/patient-reported outcome measurement—in
the trial protocol
– – SA 17 (14.8)
A 33 (28.7)
NO 23 (20.0)
D 39 (33.9)
SD 3 (2.6)
SA 6 (16.7)
A 12 (33.3)
NO 12 (33.3)
D 5 (13.9)
SD 1 (2.8)
Data collection staff in trials need more information on
quality of life/patient-reported outcome measurement—in
other trial documentation, such as SOPs
– – SA 17 (14.8)
A 54 (47.0)
NO 19 (16.5)
D 22 (19.1)
SD 3 (2.6)
SA 7 (19.4)
A 16 (44.4)
NO 8 (22.2)
D 4 (11.1)
SD 1 (2.8)
Data collection staff in trials need more information on
quality of life/patient-reported outcome measurement—
delivered in the form of trial training
– – SA 24 (21.1)
A 55 (48.2)
NO 17 (14.9)
D 17 (14.9)
SD 1 (0.9)
SA 6 (16.7)
A 14 (38.9)
NO 72 (19.4)
D 8 (22.2)
SD 1 (2.8)
It is important to explain to data collection staff, the purpose
and importance of quality of life/patient-reported outcome
data to the trial
– – SA 41 (36.3)
A 69 (61.1)
NO 3 (2.7)
D 0 (0)
SD 0 (0)
SA 13 (33.3)
A 20 (55.6)
NO 2 (5.6)
D 1 (2.8)
SD 1 (2.8)
It is important to explain to data collection staff, the
relevance and reasoning behind individual quality of life/
patient-reported outcome questions
– – SA 30 (26.1)
A 55 (47.8)
NO 18 (15.7)
D 12 (10.4)
SD 0 (0)
SA 8 (22.2)
A 22 (61.1)
NO 4 (11.1)
D 0 (0)
SD 2 (5.6)
Thinking about the future. What particular quality of life/patient-reported outcome guidance should be included the trial protocol, what should be included in trial training,
and what should be included in a standard operating procedure? (TP, trial protocol; TT, trial training; SOP, standard operating procedure)
Purpose/importance of quality of life/patient-reported
outcome data in trial
TP 389 (79.1)
TT 344 (69.9)
SOP 131 (26.6)
– TP 77 (67.5)
TT 89 (78.1)
SOP 28 (24.6)
TP 27 (87.1)
TT 23 (74.2)
SOP 15 (48.4)
How to administer the questionnaire TP 212 (43.1)
TT 403 (81.9)
SOP 275 (55.9)
– TP 43 (38.1)
TT 101 (89.4)
SOP 73 (64.6)
TP 13 (40.6)
TT 27 (84.4)
SOP 23 (71.9)
How to input quality of life/patient-reported outcome data
into the database‡
– TP 3 (11.1)
TT 22 (81.5)
SOP 18 (66.7)
– –
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Table 2 Continued
Survey questions and response options
No. (%) research
nurse
respondents* (n=560)
No. (%) data manager
respondents* (n=41)
No. (%) trial manager
respondents* (n=129)
No. (%) chief and principal
investigator respondents*
(n=37)
When to administer the questionnaire TP 359 (73.9) TT 328
(67.5) SOP 202 (41.6)
– TP 88 (77.2)
TT 95 (83.3)
SOP 64 (56.1)
TP 23 (71.9)
TT 28 (87.5)
SOP 21 (65.6)
What to do if there are missing data or in the event of
scoring errors (eg, two answers provided instead of one, or
reversed scoring)‡
– TP 2 (7.3)
TT 19 (67.3)
SOP 28 (78.2)
– –
What to do if participants write additional information on
their questionnaires (or attach a letter)
TP 178 (36.3)
TT 405 (82.5)
SOP 232 (47.3)
TP 3 (10.7)
TT 20 (71.4)
SOP 28 (64.3)
TP 14 (12.7)
TT 83 (75.5)
SOP 78 (70.9)
TP 5 (15.6)
TT 25 (78.1)
SOP 22 (68.8)
Ethical issues associated with quality of life/patient-reported
outcome use
TP 253 (52.5)
TT 345 (71.6)
SOP 180 (37.3)
– TP 57 (56.4)
TT 68 (67.3)
SOP 36 (35.6)
TP 12 (40.0)
TT 24 (80.0)
SOP 16 (53.3)
How to deal with upset patients (communication/
counselling skills)
TP 71 (15.2)
TT 390 (83.7)
SOP 204 (43.8)
– TP 6 (6.0)
TT 91 (91.0)
SOP 50 (50.0)
TP 6 (18.8)
TT 29 (90.6)
SOP 17 (53.1)
Working with non-English language patients TP 248 (51.8)
TT 329 (68.7)
SOP 284 (59.3)
– TP 39 (38.2)
TT 80 (78.4)
SOP 66 (64.7)
TP 18 (58.1)
TT 24 (77.4)
SOP 20 (64.5)
How to support the participant to answer sensitive
questions
TP 76 (15.9)
TT 429 (89.7)
SOP 180 (37.7)
– TP 4 (3.7)
TT 100 (92.6)
SOP 45 (41.7)
TP 8 (27.6)
TT 27 (93.1)
SOP 19 (65.5)
How to collect quality of life/patient-reported outcome data
without biasing the results
TP 190 (38.7)
TT 412 (83.9)
SOP 265 (54.0)
– TP 32 (28.6)
TT 98 (87.5)
SOP 63 (56.3)
TP 9 (28.1)
TT 29 (90.6)
SOP 21 (65.1)
Collecting quality of life/patient-reported outcome data in
different patient groups and/or settings
TP 145 (30.3)
TT 381 (79.9)
SOP 220 (46.0)
– TP 24 (25.0)
TT 75 (78.1)
SOP 42 (43.8)
TP 12 (41.4)
TT 23 (79.3)
SOP 16 (55.2)
Relevance and reasoning behind individual quality of life/
patient-reported outcome questions
TP 269 (55.1)
TT 371 (76.0)
SOP 94 (19.3)
– TP 50 (54.3)
TT 66 (71.7)
SOP 17 (18.5)
TP 12 (42.9)
TT 23 (82.1)
SOP 10 (35.7)
How to deal with difficult situations. TP 71 (15.2)
TT 391 (83.7)
SOP 94 (45.6)
– TP 2 (2.0)
TT 88 (88.9)
SOP 41 (41.4)
TP 5 (16.7)
TT 27 (90.0)
SOP 22 (73.3)
A, agree; D, disagree; N, no; NO, no opinion; SA, strongly agree; SD, strongly disagree; SOP, standard operating procedure; TP, trial protocol; TT, trial training; Y, yes.
*Columns may not add up to n due to missing values.
†Respondents were able to select multiple categories. Full survey data set available in online supplementary file 2.
‡Data manager respondents only.
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provided: in the trial protocol, in trial training or in sup-
porting trial documentation such as SOPs. In general, all
groups supported the inclusion of the majority of pro-
posed PRO guidance within trial training and/or a SOP,
but there was less support for including items within the
protocol. In order to highlight where there was agree-
ment on the necessary components of PRO guidance,
items that were selected by more than 50% of respon-
dents in a professional group are presented in table 3.
Free-text comments regarding future PRO guidance
There were 22 free-text comments in this section. These
most commonly suggested that trial protocols should
signpost sources of PRO information, rather than
include the information themselves:
I think that mention of some things within the Protocol
could be quite short e.g. ‘how to deal with difﬁcult situa-
tions will be covered in trial training and in SOP xxx
date yyy’. (Research nurse)
Some comments indicated PRO training should be
conducted outside of the trial:
some of this could be generic to many trials so may be
able to train as ‘general training’ via R&D depts rather
than trial speciﬁc training via CTUs. (Research nurse)
Two research nurses each suggested one additional
element of PRO guidance, but the optimal location was
not speciﬁed:
whether the questionnaire should always be answered by
the individual or whether it can be used by family/
friends on the patient’s behalf. (Research nurse)
how to answer when a question is ambiguous or the
[information] given does not ﬁt in with the suggested
answer. (Research nurse)
Finally, one research nurse highlighted the import-
ance of including PROM guidance in the participant
information:
You haven’t asked about putting this into the [partici-
pant] info sheets which is very important. The patients
need to know exactly what is required of them….
(Research nurse)
DISCUSSION
Principal findings
The survey ﬁndings support the generalisability of our
previous qualitative evidence,13 suggesting there are
inconsistencies in the way PROMs are administered by
trial personnel, with regard to: the level of assistance
given to participants during PROM completion; the
timing with which PROMs are completed in relation to
the clinical consultation; and the way missing PRO data
are monitored and acted on.
This variability in PRO administration practice is prob-
lematic on two fronts. Where it exists between trials, it
may lessen the conﬁdence with which different PRO
trial results may be compared by key stakeholders,
including: patients, clinicians, regulatory authorities and
policymakers. Where variability is present in a single
trial, however, it raises a number of concerns. First,
marked differences reported in the level of assistance
given to trial participants during PRO assessment may
result in measurement variability within the study, redu-
cing the quality of the trial data. In addition, increased
assistance given to some participants could lead to
response bias.22 Second, the practice of administering
PROM questionnaires after a clinical consultation may
lead to PRO data contamination, as, if a participant
receives bad news or undergoes an invasive procedure,
this may colour their questionnaire responses.20 Our
data suggest that the timing of questionnaire delivery
may not be consistent between individual trial staff;
therefore, it may not be possible to compensate in the
analyses for this potential confounder. Third, variation
seen in the management of missing PRO data risks
introducing bias, as data are more likely to be missing
from those participants in a trial with the poorest out-
comes,6–8 10 who may be concentrated in a particular
arm of the trial, for example, if one intervention in the
study results in greater levels of side effects or toxicity.23
In our sample, over one-ﬁfth of research nurses and
data manager respondents reported that they did not
check completed PROMs for missing data. In addition,
only 50% of research nurses and 15% of data man-
agers/coordinators who did report checking, subse-
quently followed up with participants to ensure the
missing items or questionnaires were completed. It is
concerning that a sizeable proportion of staff did not
routinely check for missing PRO data; however, the low
rates of follow-up across all data collection personnel are
equally worrying: there is little point in monitoring
missing data if nothing is performed to rectify the situ-
ation. These ﬁndings suggest that a formal procedure
needs to be in place for monitoring and responding to
missing PRO items/questionnaires in trials.
Communicating this procedure to all frontline staff may
help prevent the relatively high rates of missing PRO
data seen in some studies.5 Failure to standardise PRO
assessment methods and minimise avoidable missing
data reduces data quality, misuses valuable participant
time and research resources, risks the introduction of
bias and ultimately devalues these important patient-
centred outcomes, undermining their usefulness in
informing policy, regulatory decisions and patient care,
resulting in ‘research waste’.6 24
Our previous qualitative data suggested a lack of
PRO-speciﬁc guidance in the trial protocol and in the
form of trial training.13 The survey ﬁndings revealed
mixed opinions in this area. Over two-thirds of trial man-
agement respondents reported giving instructions to data
collection staff on how to administer the PROM
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questionnaire. Research nurses concurred that PRO
information was commonly present in the protocol,
whereas only half of data managers agreed. The research
nurse reports are, however, at odds with other available
evidence. A recent review of the PRO content of trial pro-
tocols25 found that instructions on the PRO rationale/
hypothesis, data collection methods, training and man-
agement were frequently absent from the protocols, even
when the PRO was the primary outcome. Research nurse
free-text comments in the survey appeared to align with
these ﬁndings, suggesting that PRO protocol content
could often consist of little more than a statement outlin-
ing that a PROM would be collected.
There was, however, some agreement between staff
groups regarding levels of PRO training. Less than
one-third of research nurses and less than two-ﬁfths of
data managers reported receiving trial training that
incorporated PRO guidance. Moreover, some staff
reported PRO-speciﬁc training provision was inconsistent
across trials and that training was not generally access-
ible for staff entering a trial once it was underway.
Some research nurses in our survey questioned the
usefulness of PRO-speciﬁc trial guidance, appearing to
rely on their experience and judgement instead. Also,
our regression model indicated that staff with greater
experience (≥10 years) tended to report dealing more
appropriately with missing PRO data, presumably
because they had been involved in a greater number of
relevant trials, but that trial protocol content or training
were not signiﬁcant predictors. It is possible, however,
that the protocol content and training received by the
respondents did not contain adequate information on
the management of missing data. A review of PRO
protocol content25 reported that under half of the n=75
included protocols detailed plans to minimise levels of
avoidable missing PRO data.
When asked about future trials, an overwhelming
majority of research nurse and data manager respon-
dents reported that more PRO information should
be provided in trials. It would appear, however, that
respondents did not feel additional PRO-speciﬁc
content in protocols was useful and that other mediums
of information transfer, including trial training and
SOPs, might be more appropriate. Views differed regard-
ing the exact PRO information that should be provided
to each professional group, indicating that each had dif-
ferent needs. This should be taken into account during
the design of future trials collecting PROMs.
The ﬁndings of this study suggest there is a need to
develop general PRO guidance for trialists, which high-
light the key issues that should be considered by
researchers involved in trial design and implementation.
The study team are currently working to produce such
guidelines in partnership with the International Society
for Quality of Life Research ‘Best Practices for PROs in
Randomised Clinical Trials’ taskforce.
Table 3 Future patient-reported outcome guidance provision
Trial protocol Trial training SOP
Suggested PRO-specific items of information13 RN DM TM CPI RN DM TM CPI RN DM TM CPI
Purpose/importance of quality of life/patient-reported
outcome data in trial
* * * * * *
How to administer the questionnaire * * * * * *
How to input quality of life/patient-reported outcome data
into the database
* *
When to administer the questionnaire * * * * * * * *
What to do if there is missing data or in the event of
scoring errors (eg, two answers provided instead of one,
or reversed scoring)
* *
What to do if participants write additional information on
their questionnaires (or attach a letter)
* * * * * * *
Ethical issues associated with quality of life/
patient-reported outcome use
* * * *
How to deal with upset patients * * * *
Working with non-English language patients * * * * * * * *
How to support the participant to answer sensitive
questions
* * * *
How to collect quality of life/patient-reported outcome
data without biasing the results
* * * * * *
Collecting quality of life/patient-reported outcome data in
different patient groups and/or settings
* * *
Relevance and reasoning behind individual quality of life/
patient-reported outcome questions
* * * *
How to deal with difficult situations * * * *
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Strengths and limitations of the study
This study is the ﬁrst to survey the opinions of researchers
and trial personnel regarding the administration of PROs
in trials. Our large research nurse sample size should
allow reasonably conﬁdent generalisation of the results in
this population. Owing to their much smaller sample
sizes, caution should be exercised when generalising the
results from the remaining subgroups. Respondents were
self-selecting and may include those with more knowl-
edge regarding PROs; this should be taken into account
when interpreting the results of the study. As the survey
was anonymised, it was not possible to link staff together
within a particular study or study centre. We were there-
fore unable to determine to what extent the broader
population of UK study centres was represented in the
survey. In addition, further work is needed to deﬁnitively
establish whether the PRO administration variability seen
in this survey may be present in a single trial.
CONCLUSIONS
The ﬁndings of this large-scale survey of clinical trial staff
suggest there are inconsistencies in the way PROMs are
administered by trial staff, which may reduce the quality of
PRO data and have the potential to introduce bias. There
was general agreement among respondents that the provi-
sion of PRO guidance in future trials should be improved,
with the majority of information included in trial training
and SOPs, and signposted in the trial protocol.
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